Furthermore, decreases in body weight associated with GLP-1RAs differed between the CV outcomes trials, with mean body weight decreases from baseline of 2.3 kg at 36 months in the LEADER trial (median dose of liraglutide: 1.78 mg once-daily) and 3.6 and 4.9 kg at 104 weeks in the SUSTAIN-6 trial (for 0.5 and 1.0 mg once-weekly, respectively)
No statistically significant between-group difference was observed ( p = 0.65)
Many exhibit deficiencies in vital vitamins and minerals such as calcium, vitamin D, zinc, iron, and omega-3s, often due to restrictive diets high in processed foods
MIC B12 injections deliver methylcobalamin (B12), myoinositol, and choline to support energy metabolism and weight management
Small bowel obstruction is associated with a 5-10 % risk of death again depending on severity